Rapamycin
Human evidence and active trials are visible in this field
97 human-evidence records · 28 active trials · 194 visible funding records · 6,773 universities
Australian Patent Application
P53 wild-type as biomarker for the treatment with mTOR inhibitors in combination with a cytotoxic agent
Source-linked patent metadata for P53 wild-type as biomarker for the treatment with mTOR inhibitors in combination with a cytotoxic agent, including priority, record stage and longevity-topic connections.
Australian application snapshot
Patent application record
This privacy-minimal view describes one official Australian patent application record. It is not presented as a complete worldwide patent family.
- Application number
- AU2005215910
- Earliest priority
- February 23, 2004
- Application date
- August 7, 2006
- Source record
- 1
- Patent offices
- 1
Patent-to-Evidence Translation Map
What is happening in the same scientific field?
These connections share a longevity topic with this patent record. They do not prove that the listed evidence, trials, funders, or universities validate, finance, own, or support this invention.
Why names are absent
This feed intentionally excludes party names and contact details to minimise personal data. Open the official record when a name is consequential.
Topics connected by metadata
Rapamycin82% metadata match
How the patent office classifies this invention
C12Q1/68 · G01N33/574
Verify in the original patent source →